Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
United States
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Takeda in the U.S.
Worldwide Offices
Executive Leadership
Corporate Philosophy
Contact Us
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Research & Development
Our Pipeline
Therapeutic Areas
Patient Services
U.S. Product List
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
Takeda Unveils Newly Renovated Building at 500 Kendall Street
How Our Los Angeles Site Pursues Energy Independency and Helps Takeda Become a Carbon-zero Operation
Progress Promise and a Path Forward A Look Inside Takedas Wave 1 Pipeline
Partnerships as Catalysts for Innovation
In Their Shoes
The Key Elements at the Heart of Our Innovation
Caring
Advancing Health Equity Built on Trust
Takeda Redoubles DEI Efforts With Insight Action
How Takeda is thinking about value-based arrangements with payers
Heritage
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
Learn more
Commitment to Community
Employee Stories
Our Environment
Culture of Compliance
Federal
CPSIA
State
Open Payments and Transparency Reporting
Diversity and Inclusion
Independent Medical Education Grants
Takeda Pricing Philosophy
Lobbying & Political Contributions
Patient Assistance
HOME
Newsroom
Statements
Share:
Newsroom
News Releases
Statements
NATPARA Updates
COVID-19 Updates
Statements
Enter
All
Last 12 months
2020
2019
2018
2017
2016
2015
2014
April 2021
April 20, 2021
4/20/2021
Pausing to Acknowledge
September 2020
September 1, 2020
9/1/2020
Update on the U.S. Development Program for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
November 2014
November 5, 2014
11/5/2014
Takeda Update Regarding Colcrys® Litigation
October 2014
October 27, 2014
10/27/2014
Takeda Responds to Ruling in Diabetes Drug Case Expresses Continued Confidence in ACTOS
September 2014
September 3, 2014
9/3/2014
Takeda Responds to Judgment in Diabetes Drug Case Takeda Stresses Continued Confidence in ACTOS
April 2014
April 8, 2014
4/8/2014
Takeda Responds to Verdict in Diabetes Drug Case
TOP
Close
